Medexus Provides Business Update on GRAFAPEX (treosulfan) for Injection, Capital Allocation, and Investor Conference Participation
Ontario and Chicago, Illinois--(Newsfile Corp. - April 15, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today provided an operational business update on the ongoing commercialization of GRAFAPEX™ (treosulfan) for Injection in the United States and on certain recent capital allocation and capital structure developments and announced company management's participation in two upcoming investor conferences. All dollar amounts in this news release are in US dollars unle
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-04-15 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Scryb Approves Proposed Name Change and Grant of Stock Options
Toronto, Ontario--(Newsfile Corp. - April 15, 2026) - Scryb Inc. (CSE: SCYB) ("Scryb'' or the "Company"), is pleased to announce that it intends to complete its corporate name change to NorthPalm Capital Corp., marking the next phase in the Company's evolution and reflecting a renewed strategic focus on shareholder value creation and disciplined growth. Under the new NorthPalm Capital, the Company plans to focus on timing, execution, and high-growth opportunities, suppo
Biotechnology, Healthcare and Hospitals, Health
2026-04-15 11:34 AM EDT | NorthPalm Capital Corp.
Yellowbird Diagnostics Announces First Patients Dosed in Phase 1 Trial of NeuCavis(TM)
Ottawa, Ontario--(Newsfile Corp. - April 15, 2026) - Yellowbird Diagnostics Inc. today announced the successful dosing and imaging of the first participants in its Phase I clinical trial of NeuCaVis™, a novel metabolic PET imaging agent desig
Biotechnology, Pharmaceuticals
2026-04-15 7:15 AM EDT | Yellowbird Diagnostics
BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum
Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that the Company has been selected as one of the top four innovators to present its liquid biopsy platform at the annual Canadian Thoracic Society (CTS) Research Forum. The presentation will take place in front of a panel of expe
Technology, Biotechnology, Healthcare and Hospitals
2026-04-14 8:30 AM EDT | BioMark Diagnostics, Inc.
Cheelcare to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference
Markham, Ontario--(Newsfile Corp. - April 14, 2026) - Cheelcare Inc. (TSXV: CHER) (OTC: CHCRF) ("Cheelcare" or the "Company"), a Canadian innovator in advanced mobility solutions, announced today that it will participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference take place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada. Cheelcare's CEO, Eugene Cherny and VP of Growth, Allan Boyd will present and participate in one-on-one meetings wit
Technology, Biotechnology, Investment Banking, Health
2026-04-14 7:30 AM EDT | Bloom Burton & Co. Inc.
Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart
Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that Cardiol's President and Chief Executive Officer, David Elsley, will participate in a live interview on X with
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2026-04-14 7:27 AM EDT | Cardiol Therapeutics Inc.
Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma
Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the 3D analysis of telomeres (which are the ends of chromosomes) today announced the launch of a new retrospective clinical study in collaboration with leading hematologists at the National and Kapodistrian University of Athens, Dr. Meletios Dimopoulos
2026-04-14 7:00 AM EDT | Telo Genomics Corp.
Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
Encinitas, California--(Newsfile Corp. - April 14, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced the publication of the results from its Phase 1 ABACUS-1 study of KIO-301 in Nature Medicine. The publication adds clinical detail to a program aimed at restoring light responsiveness with a small molecule "photoswitch" in patients with the advanced inherited retinal disease, retinitis pigmentosa. The publication
Biotechnology, Pharmaceuticals
2026-04-14 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Marvel Biosciences Announces an Amendment to the Conversion Price for Marvel's Proposed Convertible Debenture Offering
Calgary, Alberta--(Newsfile Corp. - April 13, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") Further to the Company's press release of April 8, 2026, announcing its intention to complete a non-brokered private placement offering of unsecured convertible debentures ("Debentures") in the principal amount of up to $500,000 (the "Offering"), Marvel wishes to announce that it has amended the conversation price for the Debentures, which
2026-04-13 5:31 PM EDT | Marvel Biosciences Corp.
PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology
Toronto, Ontario--(Newsfile Corp. - April 13, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, announced it has submitted U.S. provisional patent application No. 64/0
Biotechnology, Pharmaceuticals
2026-04-13 8:00 AM EDT | PharmaTher Holdings Ltd.
ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Cambridge, Massachusetts--(Newsfile Corp. - April 13, 2026) - ProMIS Neurosciences, Inc. (NASDAQ: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that Neil Warma, Chief Executive Officer, will participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference. The conference is being held April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, O
Technology, Biotechnology, Investment Banking, Health
2026-04-13 7:30 AM EDT | Bloom Burton & Co. Inc.
WELL Health and WELLSTAR to Participate in Upcoming 2026 Bloom Burton & Co. Healthcare Investor Conference
Vancouver, British Columbia--(Newsfile Corp. - April 13, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (the "Company" or "WELL"), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, and its majority-owned
Technology, Biotechnology, Investment Banking, Health
2026-04-13 7:30 AM EDT | Bloom Burton & Co. Inc.
Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study
Toronto, Ontario--(Newsfile Corp. - April 13, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses has demonstrated a complete response of all animals treated with X-Ray-activated Rutherrin® in a preclinical animal model of M
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-04-13 7:00 AM EDT | Theralase Technologies Inc.
Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - April 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using it
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-04-13 7:00 AM EDT | Phio Pharmaceuticals Corp.
HEALWELL to Participate in Upcoming 2026 Bloom Burton & Co. Healthcare Investor Conference
Toronto, Ontario--(Newsfile Corp. - April 13, 2026) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care, is pleased to announce that the Company will be participating as a presenting company at the 2026 Bloom Burton & Co. Healthcar
Technology, Biotechnology, Investment Banking, Health
2026-04-13 7:00 AM EDT | Bloom Burton & Co. Inc.
OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor
New York, New York--(Newsfile Corp. - April 13, 2026) -
2026-04-13 6:00 AM EDT | OS Therapies
Sharp Therapeutics Updates on '901 for Gaucher and GBA1 Parkinson's and Platform Programs
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces that following longer-term non-GLP testing the company has decided to advance an alternative compound for its Gaucher and GBA1 Parkinson's programs. The company continues to advance all platform programs including programs for genetic and sporadic forms of neurodegeneration (Progranulin modulators), and a ra
2026-04-10 5:05 PM EDT | Sharp Therapeutics Corp.
Sharp Therapeutics Announces Closing of Fourth Tranche of Unsecured Convertible Note Offering
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has closed the fourth tranche (the "Fourth Tranche") of its previously announced non-brokered private placement for unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). Pursuant to
2026-04-10 5:00 PM EDT | Sharp Therapeutics Corp.
Younet AI Partners with Perpetuals.com to License and Co-Develop Forgentiq.ai Sovereign LLM and Agentic Technology Platform
Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Younet AI, the enterprise-grade private AI solutions provider, today anno
Technology, Biotechnology, Computer Software
2026-04-10 10:21 AM EDT | Younet.ai
Theralase(R) Closes $CAN 2.66 Million Financing
Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has successfully closed both a non-brokered private placement offering ("Offering
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-04-10 7:00 AM EDT | Theralase Technologies Inc.